InpharmD
InpharmD™ offers a literature search solution for clinical pharmacists, enabling them to quickly find answers to clinical questions. The platform saves significant time by performing custom literature searches, eliminating the need for manual research on platforms like UpToDate or PubMed. Trusted by over 20,000 physicians, nurse practitioners, physician assistants, and pharmacists, InpharmD™ delivers curated responses and has saved clinical pharmacists 107,582 hours, yielding a 4x ROI and 100% customer satisfaction. They focus on transforming how clinical literature is accessed and utilized, providing actionable drug information in real-time to support faster, more informed decision-making.
InpharmD
InpharmD™ offers a literature search solution for clinical pharmacists, enabling them to quickly find answers to clinical questions. The platform saves significant time by performing custom literature searches, eliminating the need for manual research on platforms like UpToDate or PubMed. Trusted by over 20,000 physicians, nurse practitioners, physician assistants, and pharmacists, InpharmD™ delivers curated responses and has saved clinical pharmacists 107,582 hours, yielding a 4x ROI and 100% customer satisfaction. They focus on transforming how clinical literature is accessed and utilized, providing actionable drug information in real-time to support faster, more informed decision-making.
TL;DR
What they do: AI-enabled drug information and one-touch literature search service that delivers curated, evidence-based answers to clinicians with pharmacist oversight.
Founded / HQ: 2018; Atlanta, United States
Funding: Seed $6,050,000 (Dec 2023), led by 645 Ventures
Customer signal: Trusted by 10,000+ clinical pharmacists and used by 30+ health systems
Team size: Approximately 41 employees
Company Overview
Problem Domain
Clinical drug information and literature searching for clinicians (notably clinical pharmacists).
Founded
2018
Industry
Healthcare / Drug information
Funding Track Record
6,050,000 USD
Round participants named by the company include Atlanta Ventures, Y Combinator, Qlarant Capital, SF ELC, and angel investors.
Investor Signal
“Seed round led by 645 Ventures with participation from Atlanta Ventures, Y Combinator, Qlarant Capital, SF ELC, and angels.”